The downregulation of COX-2 and interleukin-6 (IL-6) suggests that BT may exert anti-inflammatory effects, reducing the risk of chronic inflammation and subsequent skin damage or cancer development [40,41]. The gene discussed is PTGS2; the disease is cancer.